Anti-gp210 and anti-sp100 antibody status and ursodeoxycholic acid response in primary biliary cholangitis

Journal article

Aims: Primary biliary cholangitis is a chronic biliary liver disease, for which the prognosis is poorer in patients who do not respond satisfactorily to the mainstay of treatment, ursodeoxycholic acid. Evidence suggests the presence of primary biliary cholangitis specific antinuclear antibodies such as anti-gp210 or anti-sp100 are associated with poorer clinical outcomes, and possibly with non-response to ursodeoxycholic acid. We aimed to analyze the association between these primary biliary cholangitis-specific antinuclear antibodies, anti-gp210 and anti-sp100, and ursodeoxycholic acid response in primary biliary cholangitis. Material and methods: A retrospective audit was performed on 92 patients with primary biliary cholangitis for whom specific antinuclear antibody status and ursodeoxycholic acid response data was available. The response to ursodeoxycholic acid, assessed using Barcelona and Paris II criteria, was analyzed according to anti-gp210 and/or anti-sp100 positivity. Results: There was a non-significantly lower ursodeoxycholic acid response rate among anti-gp210 positive patients (12/18, 66.7%) compared with anti-gp210 negative patients (57/74, 77.0%, p=0.5439); and in anti-sp100 positive patients (15/21, 71.4%) compared with anti-sp100 negative patients (54/71, 76.1%, p=0.886). On univariate analysis and multivariate analysis, there was no significant change in odds of ursodeoxycholic acid response with either anti-gp210 or anti-sp100 positivity. Conclusion: This study found that there was no association between anti-gp210 or anti-sp100 antibody status and response to ursodeoxycholic acid in a European primary biliary cholangitis cohort. This is in contrast to previous literature. However there was a trend towards an association between primary biliary cholangitis-specific antinuclear antibody positivity and lower ursodeoxycholic acid response rates.

Authors: Sturrock, B; Rogers, J; Sadler, R; Ferry, B; Roberts, C

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: ACT Publishing Group Limited
• Journal: Journal of Gastroenterology and Hepatology Research
• Volume: 7
• Issue: 6
• Pages: 1-7
• Publication date: 2018-12-21
• Acceptance date: 2018-11-02
• DOI: 10.17554/j.issn.2224-3992.2018.07.797
• EISSN: 2224-6509
• ISSN: 2224-3992
• Keywords: liver cirrhosis- biliary; anti-gp210; primary biliary cholangitis; ursodeoxycholic acid; anti-sp100